SPOTLIGHT: FDA accelerates Provenge timeline


More news in the ongoing Dendreon/Provenge saga. The FDA has agreed to amend Dendreon's Special Protocol Assessment (SPA) for a Phase III trial of Provenge, the company's prostate cancer treatment candidate. The amended SPA accelerates the expected timing of the trial results by about one year. Release

Suggested Articles

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.